Opdivo for glioblastoma – pro
Clinical outcomes for glioblastoma remain poor. Treatment with immune checkpoint blockade has shown benefits in many cancer types. Data from a randomized phase 3 clinical trial evaluating a programmed death-1 (PD-1) inhibitor therapy for glioblastoma have not been reported.The CheckMate 143 Phase 3 Randomized Clinical Trial did not show improved survival benefit was not observed in patients who received nivolumab compared with bevacizumab-treated control patients.
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial also did not improve survival in newly diagnosed GBM with unmethylated MGMT promoter.
Reardon DA, Brandes AA, Omuro A, et al. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020;6(7):10031010. doi:10.1001/jamaoncol.2020.1024
Antonio Omuro, Alba A Brandes, Antoine F Carpentier, Ahmed Idbaih, David A Reardon, Timothy Cloughesy, Ashley Sumrall, Joachim Baehring, Martin van den Bent, Oliver Bähr, Giuseppe Lombardi, Paul Mulholland, Ghazaleh Tabatabai, Ulrik Lassen, Juan Manuel Sepulveda, Mustafa Khasraw, Elodie Vauleon, Yoshihiro Muragaki, Anna Maria Di Giacomo, Nicholas Butowski, Patrick Roth, Xiaozhong Qian, Alex Z Fu, Yanfang Liu, Von Potter, Alexandros-Georgios Chalamandaris, Kay Tatsuoka, Michael Lim, Michael Weller, Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial, Neuro-Oncology, 2022
Wang, X., Lu, J., Guo, G. et al. Immunotherapy for recurrent glioblastoma: practical insights and challenging prospects. Cell Death Dis 12, 299 (2021).